美国Tremfya 市场规模、份额和趋势分析报告：按应用、分销管道和细分市场预测，2025 年至 2033 年

美国Tremfya 市场规模与趋势

预计 2024 年美国Tremfya 市场规模为 30 亿美元，到 2033 年将达到 48.9 亿美元，2025 年至 2033 年的复合年增长率为 5.32%。

在美国，慢性寻常性干癣和干癣性关节炎的盛行率不断上升，这导致对先进生技药品治疗的需求不断增长。随着这些自体免疫疾病的日益普遍，人们越来越重视能够持久控制疾病并改善患者预后的治疗方法。 IL-23 抑制剂 Tremfya（guselkumab）已证明在治疗中度至重度干癣病例方面具有可靠的疗效。

Tremfya 能够持久缓解症状，且安全性良好，因此有望被更广泛地采用。包括皮肤科医生和风湿症医师在内的美国医疗保健专业人士越来越多地将 Tremfya 纳入治疗方法。这一趋势反映了人们正转向与长期管理目标相符的精准标靶生技药品。

Tremfya 在美国的商业性成长得益于杨森製药有效的行销和稳健的竞争策略。该疗法已在生技药品市场确立了显着地位，其疗效优于多种成熟疗法，包括 TNF 抑制剂和 IL-17 抑制剂。临床对比结果突显了其快速的皮肤清除和长期疗效。例如，2024 年 10 月，强生公司的 SPECTREM 研究表明，Tremfya 有效清除了头皮、脸部、手脚和生殖器等难治性牛皮癣区域，清除率高达 80%。大多数患者在 48 週内保持皮肤清洁或接近清洁。该疗法还减轻了瘙痒和疼痛等症状，显着改善了患者的生活品质。

Tremfya 在美国市场的未来成长得益于其持续的临床开发和生命週期管理策略。目前的临床试验正在评估其在克隆氏症和化脓性汗腺炎适应症的应用，并有望扩大其治疗范围。製造商也正在进行真实世界证据研究，以验证其在不同病患小组中的有效性。人们对个人化医疗和生物标记驱动治疗的兴趣日益浓厚，这推动了对 IL-23 抑制剂的需求。与专科药房的合作以及高效的分销系统正在改善重点地区的药物可及性。持续投资于医师培训和病患支援计划，增强了品牌的参与度。

目录

第一章调查方法与范围

第二章执行摘要

第三章美国Tremfya 市场变数、趋势与范围

• 市场体系展望
• 市场动态
  • 市场驱动因素分析
  • 市场限制因素分析
• 商业环境分析
  • 产业分析—波特五力分析
  • PESTLE分析
  • 管道分析
  • 专利到期分析
  • 定价分析

第四章美国Tremfya 市场：应用业务分析

• 2024 年和 2033 年应用市场占有率
• 应用程式细分仪表板
• 市场规模、预测与趋势分析（按应用，2021-2033 年）
• 斑块型干癣
• 干癣性关节炎（PsA）
• 其他的

第五章美国Tremfya 市场：通路业务分析

• 2024年及2033年分销通路市场占有率
• 分销通路细分仪表板
• 按分销管道分類的市场规模、预测和趋势分析（2021-2033 年）
• 医院药房
• 零售药局
• 网路药局

第六章 竞争态势

• 参与者概览
• 企业市场分析
• 公司分类
• 战略地图
• 公司简介/上市公司
  • Johnson & Johnson Services, Inc.

U.S. Tremfya Market Size & Trends:

The U.S. Tremfya market size was estimated at USD 3.00 billion in 2024 and is projected to reach USD 4.89 billion by 2033, growing at a CAGR of 5.32% from 2025 to 2033. The rising incidence of chronic plaque psoriasis and psoriatic arthritis in the U.S. is contributing to increased demand for advanced biologic treatments. As these autoimmune disorders become more widespread, there is a growing emphasis on therapies that offer lasting disease control and improved patient outcomes. Tremfya (guselkumab), an IL-23 inhibitor, has demonstrated reliable effectiveness in managing moderate-to-severe forms of these conditions.

Its ability to provide sustained symptom relief, combined with a well-tolerated safety profile, has supported its broader adoption. U.S. healthcare professionals, including dermatologists and rheumatologists, are increasingly incorporating Tremfya into treatment regimens. This trend reflects a shift toward precision-targeted biologics that align with long-term management goals.

Tremfya's commercial growth in the U.S. is strongly supported by Janssen Pharmaceuticals' effective marketing efforts and robust competitive strategy. The therapy has carved out a distinct position in the biologics market by demonstrating higher efficacy than several established treatments, such as TNF and IL-17 inhibitors. Clinical comparisons have highlighted its ability to deliver faster skin clearance and maintain results over time. For instance, in October 2024, Johnson & Johnson's SPECTREM study showed Tremfya effectively cleared difficult psoriasis areas like the scalp, face, hands, feet, and genitals, with clearance rates up to 80%. Most patients maintained clear or almost clear skin through week 48. The treatment also significantly improved patients' quality of life by reducing symptoms like itch and pain.

The future growth of the Tremfya market in the U.S. is supported by ongoing clinical development and lifecycle management strategies. Current trials are assessing its use in additional indications such as Crohn's disease and hidradenitis suppurativa, potentially expanding its treatment range. The manufacturer is also conducting real-world evidence research to confirm its effectiveness across varied patient groups. Rising interest in personalized medicine and biomarker-focused treatments is boosting demand for IL-23 inhibitors. Collaborations with specialty pharmacies and efficient distribution systems improve access in key regions. Continued investment in physician training and patient support initiatives strengthens brand engagement.

U.S. Tremfya Market Report Segmentation

This report forecasts revenue growth at a country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. Tremfya market report based on application and distribution channel:

• Application Outlook (Revenue, USD Billion, 2021 - 2033)
• Plaque Psoriasis
• Psoriatic Arthritis (PsA)
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Application
  • 1.2.2. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Tremfya Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Tremfya Market: Application Business Analysis

• 4.1. Application Market Share, 2024 & 2033
• 4.2. Application Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Application, 2021 to 2033 (USD Billion)
• 4.4. Plaque Psoriasis
  • 4.4.1. Plaque Psoriasis Market, 2021 - 2033 (USD Billion)
• 4.5. Psoriatic Arthritis (PsA)
  • 4.5.1. Psoriatic Arthritis (PsA) Market, 2021 - 2033 (USD Billion)
• 4.6. Others
  • 4.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. U.S. Tremfya Market: Distribution Channel Business Analysis

• 5.1. Distribution Channel Market Share, 2024 & 2033
• 5.2. Distribution Channel Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 5.4. Hospital Pharmacies
  • 5.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 5.5. Retail Pharmacies
  • 5.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 5.6. Online Pharmacies
  • 5.6.1. Online Pharmacies Market, 2021 - 2033 (USD Billion)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Johnson & Johnson Services, Inc.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Application Benchmarking
    • 6.5.1.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 U.S. Tremfya market, by application, 2021 - 2033 (USD Billion)
• Table 4.U.S. Tremfya market, by distribution channel, 2021 - 2033 (USD Billion)

List of Figures

• Fig. 1 U.S. Tremfya market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Therapeutic approach and application outlook (USD Billion)
• Fig. 10 Competitive landscape
• Fig. 11 U.S. Tremfya market dynamics
• Fig. 12 U.S. Tremfya market: Porter's five forces analysis
• Fig. 13 U.S. Tremfya market: PESTLE analysis
• Fig. 14 Application market, 2021 - 2033 (USD Billion)
• Fig. 15 Plaque psoriasis market, 2021 - 2033 (USD Billion)
• Fig. 16 Psoriatic Arthritis (PsA) market, 2021 - 2033 (USD Billion)
• Fig. 17 Others market, 2021 - 2033 (USD Billion)
• Fig. 18 Distribution Channel market, 2021 - 2033 (USD Billion)
• Fig. 19 Hospital pharmacies market, 2021 - 2033 (USD Billion)
• Fig. 20 Retail pharmacies market, 2021 - 2033 (USD Billion)
• Fig. 21 Online pharmacies market, 2021 - 2033 (USD Billion)
• Fig. 22 U.S. Tremfya market revenue, by region
• Fig. 23 Country marketplace: Key takeaways
• Fig. 24 U.S. country dynamics
• Fig. 25 U.S. Tremfya market, 2021 - 2033 (USD Billion)
• Fig. 26 Company categorization
• Fig. 27 Company market position analysis
• Fig. 28 Strategic framework